复合菌群TY - T1的方案为非结核mycobacterial lung disease lack early bactericidal activity JF - European Respiratory Journal JO - Eur Respir J SP - 1000 LP - 1002 DO - 10.1183/13993003.00925-2015 VL - 47 IS - 3 AU - Slaats, Michiel H.C. AU - Hoefsloot, Wouter AU - Magis-Escurra, Cecile AU - Boeree, Martin J. AU - Wattenberg, Melanie AU - Kuipers, Saskia AU - van Ingen, Jakko Y1 - 2016/03/01 UR - //www.qdcxjkg.com/content/47/3/1000.abstract N2 - Over recent decades, nontuberculous mycobacteria (NTM) have been increasingly recognised as causative agents of pulmonary infections in humans [1]. Mycobacterium avium complex (MAC) bacteria are the most common NTM species causing pulmonary disease in humans [1]. Pulmonary disease caused by NTM (NTM-PD) usually presents as either nodular–bronchiectatic or fibrocavitary disease. NTM-PD requires complex multidrug antibiotic treatment to be continued for 12 months after culture conversion, typically for 18 months in total [1]. Despite this intensive treatment, good clinical and microbiological outcomes can only be attained in 60% of patients with MAC pulmonary disease [2]. Outcomes in nodular–bronchiectatic MAC pulmonary disease are better, with prolonged culture conversion attainable in up to 85% of patients [3].Treatment regimens for NTM lung disease lack early bactericidal activity and must be improved http://ow.ly/UyFdu ER -